Stockscreener 앱 받기
34.57
1.41%
0.48
시장 영업 전:
32.80
-1.77
-5.12%
전일 마감가:
$34.09
열려 있는:
$34.19
하루 거래량:
207.71K
Relative Volume:
0.71
시가총액:
$1.54B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-9.10%
1개월 성능:
-16.33%
6개월 성능:
+49.91%
1년 성능:
+133.58%
1일 변동 폭
$33.60
$35.93
1주일 범위
$32.56
$38.37
52주 변동 폭
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
34.57 | 1.52B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
모두보기
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Sionna backs cystic fibrosis trials with $310M cash runway to 2028 - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics, Inc. (SION) Stock Analysis: A Promising 24% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Citizens Initiates Coverage of Sionna Therapeutics (SION) with Market Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Market Recap: Is FIVE in a consolidation phase2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cystic fibrosis drug developer Sionna heads to key March investor events - Stock Titan
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences - The Manila Times
Sionna Therapeutics, Inc. (SION) Stock Analysis: A High-Stakes Bet on Biotech Innovation with 20.13% Upside Potential - DirectorsTalk Interviews
Is Sionna Therapeutics Inc. still a buy after recent gainsJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - mfd.ru
Fed Meeting: Will Sionna Therapeutics Inc outperform tech stocks2025 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit - Yahoo Finance
2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR - AD HOC NEWS
Sionna Therapeutics, Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
Can Sionna Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Breakouts & Technical Confirmation Alerts - mfd.ru
What’s the MACD signal for Sionna Therapeutics Inc.July 2025 Outlook & Risk Adjusted Buy/Sell Alerts - mfd.ru
Volume Recap: Should you avoid Sionna Therapeutics Inc stock right nowEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Orbimed Advisors Llc Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Peter Thompson Sells 29,063 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - Defense World
Sionna Therapeutics (NASDAQ:SION) Shares Down 14.6% on Insider Selling - Defense World
Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling - MarketBeat
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com Australia
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m By Investing.com - Investing.com South Africa
Thompson Peter a. sells Sionna Therapeutics (SION) shares for $1.37m - Investing.com Canada
Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 29,063 Shares - MarketBeat
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - markets.businessinsider.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $1,295,628.54 in Stock - MarketBeat
Support Test: Whats the outlook for Sionna Therapeutics Incs sectorTrade Risk Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TPG GP A, LLC Reduces Stake in Sionna Therapeutics Inc - GuruFocus
Sionna Therapeutics, Inc. (SION) Stock Analysis: Biotech’s Promising Prospects with 5.7% Upside Potential - DirectorsTalk Interviews
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Sionna Therapeutics Inc 주식 (SION) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| ORBIMED ADVISORS LLC | Director |
Feb 03 '26 |
Sale |
44.58 |
29,063 |
1,295,629 |
3,530,702 |
| ORBIMED ADVISORS LLC | Director |
Feb 02 '26 |
Sale |
44.57 |
1,890 |
84,237 |
3,559,765 |
| TPG GP A, LLC | 10% Owner |
Jan 22 '26 |
Sale |
40.00 |
250,000 |
10,000,000 |
6,494,962 |
0.11%
6.00%
자본화:
|
볼륨(24시간):